A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

This study has been completed.

First Received: January 3, 2003 Last Updated: August 4, 2008 History of Changes

Sponsor:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00051142

Purpose

The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.

Condition	Intervention	Phase
Glaucoma, Open-Angle Ocular Hypertension	Drug: Travoprost Drug: Latanoprost	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Latanoprost Travoprost

U.S. FDA Resources

Further study details as provided by Alcon Research:

Study Start Date:	February 2001
Study Completion Date:	June 2004
Primary Completion Date:	June 2004 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Adult patients of any race and either sex with open-angle glaucoma (with or without pigment dispersion or pseudoexfoliation component) or ocular hypertension.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051142

Locations

United States, Texas
Latin America
Fort Worth, Texas, United States

Sponsors and Collaborators

Alcon Research

Investigators

Principal Investigator:

Alcon Investigators

Alcon Research

More Information

No publications provided

Study ID Numbers:	C-01-36
Study First Received:	January 3, 2003
Last Updated:	August 4, 2008
ClinicalTrials.gov Identifier:	NCT00051142 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

Glaucoma
POAG
OAG
OHT

Additional relevant MeSH terms:

Eye Diseases
Vascular Diseases
Cardiovascular Agents
Latanoprost
Antihypertensive Agents
Pharmacologic Actions
Travoprost

Glaucoma
Glaucoma, Open-Angle
Therapeutic Uses
Cardiovascular Diseases
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on November 09, 2009